Financials data is unavailable for this security.
View more
Year on year China Resources Pharmaceutical Group Ltd grew revenues 12.16% from 218.18bn to 244.70bn while net income improved 10.11% from 3.50bn to 3.85bn.
| Gross margin | 15.78% |
|---|---|
| Net profit margin | 3.31% |
| Operating margin | 4.65% |
| Return on assets | 3.19% |
|---|---|
| Return on equity | 7.95% |
| Return on investment | 12.13% |
More ▼
Cash flow in CNYView more
In 2023, China Resources Pharmaceutical Group Ltd increased its cash reserves by 61.92%, or 9.43bn. The company earned 15.55bn from its operations for a Cash Flow Margin of 6.35%. In addition the company used 2.07bn on investing activities and also paid 4.07bn in financing cash flows.
| Cash flow per share | 1.98 |
|---|---|
| Price/Cash flow per share | 2.70 |
| Book value per share | 8.27 |
|---|---|
| Tangible book value per share | 3.25 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.37 |
|---|---|
| Quick ratio | 1.12 |
| Total debt/total equity | 1.57 |
|---|---|
| Total debt/total capital | 0.4396 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 9.16% and 10.11%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.72% |
|---|---|
| Div growth rate (5 year) | 7.05% |
| Payout ratio (TTM) | 39.44% |
| EPS growth(5 years) | 2.81 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 2.57 |
More ▼
